Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
METROCREAM vs METRETON
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Metrocream contains metronidazole, a nitroimidazole antibiotic. Its mechanism involves reduction of the nitro group by bacterial nitroreductases, forming toxic intermediates that damage DNA and inhibit nucleic acid synthesis. It also exhibits anti-inflammatory effects by reducing reactive oxygen species and modulating neutrophil chemotaxis.
Antihistamine and mast cell stabilizer. Competitively inhibits histamine at H1 receptors and prevents release of histamine and other mediators from mast cells.
Rosacea (inflammatory papules and pustules),Topical treatment of bacterial vaginosis (off-label)
Seasonal allergic conjunctivitis,Perennial allergic conjunctivitis,Other allergic ocular conditions
Topical, apply a thin film to affected area once or twice daily.
1-2 mg/kg intramuscularly or intravenously every 6-8 hours as needed; maximum 100 mg per dose.
Terminal elimination half-life: 6-8 hours. Not extended in renal impairment.
Terminal elimination half-life is 24-36 hours; increased in renal impairment (up to 60 hours in anuria)
Hepatic metabolism via oxidation and glucuronidation. Metronidazole is metabolized by CYP450 enzymes, primarily CYP2A6 and CYP3A4, forming metabolites such as hydroxy metronidazole and acetic acid metabolite.
Not extensively metabolized; primarily excreted unchanged in urine.
Renal: 70-80% as unchanged drug and metabolites. Fecal/biliary: ~20%.
Renal (80-90% as unchanged drug and metabolites), biliary/fecal (10-20%)
Metronidazole: <20% bound to plasma proteins.
75-85% bound to albumin and alpha-1-acid glycoprotein
Vd: ~0.6-0.7 L/kg, indicating distribution into total body water.
0.5-1.0 L/kg; indicates moderate tissue distribution
Topical: Systemic bioavailability approximately 0.1-1% of applied dose for metronidazole 1% cream.
Oral: 50-70% (first-pass metabolism); Intramuscular: 80-100%
No adjustment required for topical application.
Cr Cl 10-50 m L/min: administer every 12 hours; Cr Cl <10 m L/min: administer every 12-18 hours or consider dose reduction by 50%.
No adjustment required for topical application.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use or reduce dose by 75%.
Safety and efficacy not established in pediatric patients under 18 years.
0.5-1 mg/kg intramuscularly or intravenously every 6-8 hours; maximum 25 mg per dose for children <40 kg.
No specific dose adjustment recommended; use caution due to potential skin atrophy.
Start at lower end of dosing range (e.g., 0.5-1 mg/kg) with extended intervals (every 8-12 hours) due to decreased renal function and increased sensitivity.
None
None
Avoid contact with eyes. Use with caution in patients with blood dyscrasias or history of hypersensitivity to metronidazole. Prolonged use may result in overgrowth of non-susceptible organisms. Discontinue if irritation occurs.
Do not inject; for ophthalmic use only.,May cause transient burning or stinging.,Use with caution in patients with narrow-angle glaucoma.
Hypersensitivity to metronidazole or any component of the formulation.
Hypersensitivity to any component of the formulation
No significant food interactions due to negligible systemic absorption. However, alcohol consumption should be avoided during treatment and for at least 48 hours after discontinuing metronidazole, as trace systemic absorption may cause disulfiram-like reactions (nausea, vomiting, flushing, headache).
Avoid excessive alcohol intake (increases risk of lactic acidosis). No specific food restrictions, but consistent carbohydrate intake is recommended to prevent hypoglycemia. Grapefruit may increase metformin levels (use caution).
Topical metronidazole (Metro Cream) is considered low risk for teratogenicity. In animal studies, no evidence of fetal harm was observed at topical doses. For oral metronidazole, data do not suggest an increased risk of major malformations; however, use in first trimester is generally avoided due to theoretical risk. For topical application, systemic absorption is minimal (approximately 2%), and the drug is considered safe throughout pregnancy, with no known fetal risks.
Pregnancy Category C: Fetal risk cannot be ruled out. First trimester: Increased risk of cleft palate and cardiac malformations due to corticosteroid component (prednisolone). Second and third trimesters: Potential for intrauterine growth restriction, adrenal suppression in neonate. Avoid use unless benefit outweighs risk.
Minimal systemic absorption of metronidazole after topical application (approximately 2%) results in negligible transfer into breast milk. M/P ratio is not established for topical route. Use during breastfeeding is considered compatible; however, avoid application to breast area to prevent infant exposure.
Prednisolone and chlorpheniramine (components of METRETON) are excreted into breast milk. M/P ratio for prednisolone is approximately 0.5-0.7. Low risk at maternal doses <20 mg/day; higher doses may cause infant adrenal suppression or growth delay. Consider alternative antihistamine with lower excretion.
No dosage adjustment is necessary during pregnancy. Systemic absorption from topical application is minimal and pharmacokinetic changes in pregnancy do not warrant dose modification.
No specific dose adjustment required; use lowest effective dose for shortest duration. Pharmacokinetic changes in pregnancy (increased volume of distribution, hepatic metabolism) may reduce efficacy of standard doses; monitor clinical response and consider dose titration. Avoid high-dose or prolonged therapy.
Metronidazole topical cream is contraindicated in patients with a history of hypersensitivity to metronidazole or other nitroimidazole derivatives. Avoid contact with eyes, mucous membranes, or open wounds. Use during pregnancy only if clearly needed (FDA category B). Warn patients that topical metronidazole may cause transient skin irritation or dryness; if severe, discontinue use. Combine with sunscreen and photoprotective measures due to potential photosensitivity. For rosacea, clinical improvement may take 3–4 weeks; adherence is critical. Do not use with concomitant oral metronidazole or disulfiram-like reactions due to minimal systemic absorption.
METRETON is a fixed-dose combination of metformin and sitagliptin. Use with caution in patients with renal impairment (check e GFR before initiation; contraindicated if e GFR <30 m L/min/1.73 m²). Monitor for lactic acidosis, especially in hypoxic states or hepatic impairment. Discontinue temporarily before iodinated contrast imaging and for surgery. Assess for pancreatitis (discontinue if suspected). Do not use in type 1 diabetes or diabetic ketoacidosis. Dose adjustment of sitagliptin needed if e GFR 30-45 m L/min/1.73 m² (50 mg daily).
Apply a thin layer to affected areas once or twice daily as directed.,Wash hands before and after application; avoid contact with eyes, mouth, and nostrils.,Do not use cosmetics or other skin products on treated areas unless approved by your doctor.,May cause mild stinging, burning, or dryness; if severe, stop use and inform your physician.,Minimize sun exposure and use sunscreen daily as metronidazole may increase sun sensitivity.,Notify your doctor if you develop signs of allergic reaction: rash, itching, swelling, or trouble breathing.,Do not use more than prescribed; extended use may lead to bacterial resistance.,If you are pregnant, planning to become pregnant, or breastfeeding, discuss with your doctor before using.,Inform your doctor if you are taking oral metronidazole or have a history of blood disorders or neuropathy.
Take with meals to reduce gastrointestinal side effects.,Do not drink excessive alcohol while taking this medication.,Monitor for symptoms of lactic acidosis (unusual tiredness, muscle pain, trouble breathing, stomach pain) and pancreatitis (severe stomach pain, nausea, vomiting).,Inform your doctor if you become pregnant or plan to breastfeed.,Report any signs of allergic reaction (rash, hives, swelling of face/lips/throat) immediately.,Maintain adequate fluid intake, especially during illness or in hot weather.,Do not skip meals or drastically reduce carbohydrate intake without consulting your provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about METROCREAM vs METRETON, answered by our medical review team.
METROCREAM is a Antibiotic (Nitroimidazole) that works by Metrocream contains metronidazole, a nitroimidazole antibiotic. Its mechanism involves reduction of the nitro group by bacterial nitroreductases, forming toxic intermediates that damage DNA and inhibit nucleic acid synthesis. It also exhibits anti-inflammatory effects by reducing reactive oxygen species and modulating neutrophil chemotaxis.. METRETON is a Antibiotic (Nitroimidazole) that works by Antihistamine and mast cell stabilizer. Competitively inhibits histamine at H1 receptors and prevents release of histamine and other mediators from mast cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between METROCREAM and METRETON depend on the specific clinical indication. These are both Antibiotic (Nitroimidazole) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of METROCREAM is: Topical, apply a thin film to affected area once or twice daily.. The standard adult dose of METRETON is: 1-2 mg/kg intramuscularly or intravenously every 6-8 hours as needed; maximum 100 mg per dose.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between METROCREAM and METRETON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. METROCREAM is classified as Category C. Topical metronidazole (MetroCream) is considered low risk for teratogenicity. In animal studies, no evidence of fetal harm was observed at topical doses. For oral metronidazole, da. METRETON is classified as Category C. Pregnancy Category C: Fetal risk cannot be ruled out. First trimester: Increased risk of cleft palate and cardiac malformations due to corticosteroid component (prednisolone). Seco. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.